Hims & Hers Health (NYSE:HIMS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Hims & Hers Health (NYSE:HIMS) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

HIMS has been the topic of several other research reports. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Citigroup dropped their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. TD Cowen upped their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Finally, Truist Financial increased their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $32.43.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $28.50 on Friday. The company has a market cap of $6.65 billion, a P/E ratio of -45.24 and a beta of 2.40. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. The business’s 50 day moving average price is $32.14 and its 200-day moving average price is $26.05. Hims & Hers Health has a fifty-two week low of $13.74 and a fifty-two week high of $65.30.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The company had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business’s quarterly revenue was up 38.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.17 EPS. Sell-side analysts predict that Hims & Hers Health will post -0.05 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In related news, insider Irene Becklund sold 4,490 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $141,435.00. Following the transaction, the insider owned 6,790 shares of the company’s stock, valued at $213,885. This represents a 39.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Patrick Harrison Carroll sold 23,726 shares of the firm’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $35.00, for a total value of $830,410.00. Following the transaction, the insider owned 181,861 shares in the company, valued at $6,365,135. The trade was a 11.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 75,176 shares of company stock valued at $2,523,401 in the last ninety days. Corporate insiders own 11.76% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Kelly Lawrence W & Associates Inc. CA purchased a new position in shares of Hims & Hers Health during the second quarter valued at $11,520,000. Bank of New York Mellon Corp purchased a new stake in Hims & Hers Health in the second quarter worth about $46,220,000. Handelsbanken Fonder AB lifted its stake in Hims & Hers Health by 4.0% in the second quarter. Handelsbanken Fonder AB now owns 60,000 shares of the company’s stock worth $2,080,000 after acquiring an additional 2,300 shares during the period. Valeo Financial Advisors LLC purchased a new stake in Hims & Hers Health in the second quarter worth about $225,000. Finally, FNY Investment Advisers LLC bought a new position in Hims & Hers Health during the 2nd quarter worth about $347,000. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.